Atrial fibrillation (AF), the most common form of sustained arrhythmia, is rising steadily in incidence1. This progressive disorder typically begins with structural and functional derangement of the left atrium (LA) and ultimately leads to left ventricular (LV) dilation and impaired systolic and diastolic function, commonly evolving from a paroxysmal to a persistent form2. AF is characterized by structural, electrical, and contractile remodeling of the atrium. It is also associated with systemic inflammation and diffuse fibrosis, which eventually give rise to fibrotic and inflammatory changes in the ventricle as well3. A growing body of evidence indicates that myocardial fibrosis and inflammation are closely linked to the pathogenesis of AF4. Pathological studies have confirmed that patients with AF exhibit diffuse myocardial fibrosis of the left ventricle5.
Cardiovascular magnetic resonance (CMR) offers multi-parameter, multi-plane, and multi-sequence imaging, enabling comprehensive evaluation of the heart's structure, function, blood flow, and tissue characteristics. Its clinical application value is receiving increasing attention. Conventional imaging techniques (late gadolinium enhancement and T2WI) are mostly qualitative or semi-quantitative and are helpful for evaluating focal myocardial lesions. However, they have significant limitations for diffuse lesions and early micro-lesions6. The CMR quantitative techniques (T1 mapping, T2 mapping, and ECV) have effectively addressed this deficiency. T1 and T2 mapping are inherent properties of the tissue, representing the longitudinal and transverse relaxation times of the tissue, respectively. The extracellular volume fraction (ECV) refers to the percentage of the extracellular matrix volume in the total myocardial volume7. Theoretically, normal myocardial tissue has fixed values of T1, T2 mapping, and ECV under the same conditions. In disease states, pathological changes occur in the myocardial cells and/or the interstitial matrix, and these values will also change accordingly. T1 mapping, T2 mapping, and ECV of CMR allow quantitative assessment of myocardial fibrosis and inflammation8,9.
Studies have shown that quantitative CMR techniques were significantly influenced by factors such as the manufacturer of the scanning equipment, field strength, and even the sequence, and it is recommended to establish normal reference values suitable for this center based on different equipment, field strengths, and sequences7. Studies10have shown that the normal global T1 and T2 reference values on a 3.0T MR scanner were 1193 ms ± 34 ms and 36 ms ± 2.5 ms, respectively. Another meta-analysis11 on native T1 and ECV in the normal population showed that the pooled mean of native T1 was 976 msec (95% confidence interval [CI]: 969 ms, 983 ms) at 1.5 T and 1159 ms (95% CI: 1143 ms, 1175 ms) at 3.0 T; the pooled mean of ECV was 25.9% at 1.5 T (95% CI: 25.5%, 26.3%) and 3.0 T (95% CI: 25.4%, 26.5%). An inverse linear relationship has been reported between the post-contrast native T1 time of the LV myocardium and the overall degree of myocardial fibrosis12,13. LV T1 mapping can serve as a quantitative indicator of increased myocardial fibrosis in patients with hypertrophic cardiomyopathy14, non-ischemic dilated cardiomyopathy15, and acute or chronic myocardial infarction16. Studies have further shown that LV myocardial interstitial fibrosis in patients with AF is closely related to cardiac dysfunction17,18, and that patients with AF display higher T1 and T2 mapping values than those without AF19. The present study quantitatively analyzed atrial and ventricular function, along with tissue characteristics (T1 mapping, T2 mapping, and ECV), in patients with AF, providing comprehensive quantitative data to inform treatment strategies.